译语翻译分享-中国国药新冠疫苗获世卫组织紧急使用认证，世卫组织：建议不设定接种年龄上限

中国国药新冠疫苗获世卫组织紧急使用认证，世卫组织：建议不设定接种年龄上限

Sinopharm's new crown vaccine has been certified by the WHO for emergency use. WHO: It is recommended not to set an upper limit for vaccination age

 

当地时间7日下午，世界卫生组织宣布，由中国医药集团、北京生物制品研究所研发的 新冠灭活疫苗 正式通过世卫组织紧急使用认证，成为第6种获得世卫组织安全性、有效性和质量验证的新冠疫苗。世卫专家表示，中国国药新冠疫苗安全有效，其预防重症和住院的有效率可达79%。

On the afternoon of the 7th local time, the World Health Organization announced that the new crown inactivated vaccine developed by China National Pharmaceutical Group and Beijing Institute of Biological Products has officially passed the WHO emergency use certification, becoming the sixth type to obtain the safety, effectiveness and safety of the WHO. Quality-proven new crown vaccine. WHO experts said that China's Sinopharm's new crown vaccine is safe and effective, and its effective rate of preventing severe illness and hospitalization can reach 79%.

根据世卫组织发布的临时建议，18岁以上成年人可接种两剂中国国药新冠疫苗，间隔时间为三至四周；世卫组织还建议不设定接种年龄上限，因为初步数据显示该疫苗对老年人也有保护作用。

According to the temporary recommendations issued by the WHO, adults over 18 years of age can receive two doses of the Chinese new crown vaccine, with an interval of three to four weeks; WHO also recommends not setting an upper limit for vaccination age because preliminary data shows that the vaccine is effective for the elderly. People also have a protective effect.

世卫组织在声明中指出，中国国药新冠疫苗易于储存的特点使其非常适用于资源匮乏的环境，它也是第一款携带疫苗瓶监测器的疫苗，疫苗瓶上的小标签会因疫苗受热而改变颜色，便于卫生工作者判断疫苗是否安全可用。

The WHO pointed out in the statement that the easy storage of China's Sinopharm Covid-19 vaccine makes it very suitable for resource-poor environments. It is also the first vaccine to carry a vaccine vial monitor. The small label on the vaccine vial will cause the vaccine to become heated. Change the color so that health workers can judge whether the vaccine is safe and available.

此前，世卫组织已向5种新冠疫苗颁发紧急使用认证，分别是美国辉瑞制药有限公司和德国生物新技术公司联合研发的新冠疫苗、英国阿斯利康制药公司和牛津大学联合研发的两个版本阿斯利康疫苗、美国强生公司旗下杨森制药公司研发的新冠疫苗以及美国莫德纳公司研发的新冠疫苗。

Prior to this, the WHO has issued emergency use certifications to five new crown vaccines, which are the new crown vaccine jointly developed by Pfizer Pharmaceuticals Co., Ltd. of the United States and the German Biotech Company, and two versions jointly developed by AstraZeneca Pharmaceuticals of the United Kingdom and the University of Oxford. AstraZeneca vaccine, the new crown vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, and the new crown vaccine developed by Modena of the United States.

 

From website: https://baijiahao.baidu.com/